This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →
Standalone quarter ended Sep 30, 2026: revenue up 17.7%, net profit up 25.9% year on year
PGHL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.4 pts more than Nifty Microcap 250 and 1.7 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Standalone quarter ended September 30, 2026: revenue rose 17.7% to Rs 38,249 lakh from Rs 32,492 lakh, and net profit rose 25.9% to Rs 11,151 lakh from Rs 8,854 lakh a year earlier. Operating margin before other income, interest, depreciation and tax was 39.8%, versus 37.0%. No exceptional item was booked; a Rs 3,180 lakh property-sale gain arose in June. Standalone half-year: net profit Rs 20,766 lakh; operating cash flow Rs 19,086 lakh.
Revenue and profit growth and a wider operating margin are positive for shareholders; no exceptional gain supported the latest quarter.
| Q2 FY27 | Q2 FY26 | Change | |
|---|---|---|---|
| Revenue | ₹382.5 Cr | ₹324.9 Cr | +17.7% |
| Operating profit | ₹146.2 Cr | ₹114.1 Cr | +28.1% |
| Profit after tax | ₹111.5 Cr | ₹88.54 Cr | +25.9% |
| EBITDA margin | 39.8% | 37.0% | +2.8 pp |
From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.